# Milademetan in Advanced/Metastatic Solid Tumors

> **NCT05012397** · PHASE2 · TERMINATED · sponsor: **Rain Oncology Inc** · enrollment: 40 (actual)

## Conditions studied

- Solid Tumors
- Head and Neck Carcinoma
- Cholangiocarcinoma
- Sarcoma
- Lung Adenocarcinoma
- Bladder Urothelial Carcinoma
- Stomach Adenocarcinoma
- Breast Cancer Invasive
- Ovarian Carcinoma
- Cervical Cancer
- Non Small Cell Lung Cancer
- Gastric Cancer
- Biliary Tract Cancer
- Melanoma
- Pancreas Cancer
- MDM2 Gene Amplification
- Testicular Germ Cell Tumor
- Adrenocortical Carcinoma

## Interventions

- **DRUG:** RAIN-32

## Key facts

- **NCT ID:** NCT05012397
- **Lead sponsor:** Rain Oncology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-01
- **Primary completion:** 2023-10-15
- **Final completion:** 2023-10-15
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05012397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05012397, "Milademetan in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05012397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*